A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization
1996

High Mobility Group Protein I(Y) as a Marker for Prostate Cancer Progression

Sample size: 102 publication Evidence: moderate

Author Information

Author(s): Y Tamimi, HG van der Poell, HFM Karthaus, FMJ Debruyne, JA Schalken

Primary Institution: University Hospital Nijmegen

Hypothesis

High mobility group protein I(Y) might be a potential prognostic marker in prostate cancer.

Conclusion

High HMG-I(Y) levels are indicative of a worse prognosis in prostate cancer patients.

Supporting Evidence

  • 75% of samples showed appropriate RNA preservation.
  • High HMG-I(Y) expression was found in 87% of recurrent tumors.
  • Statistically significant differences in HMG-I(Y) expression levels were found between all groups.

Takeaway

This study looked at a protein that might help doctors predict how bad prostate cancer will get. They found that higher levels of this protein usually mean the cancer is more serious.

Methodology

The study analyzed HMG-I(Y) mRNA expression in paraffin-embedded archival material from 102 patients using RNA in situ hybridization.

Limitations

The study relied on archival material, which may limit the accuracy of the findings.

Participant Demographics

Patients undergoing radical prostatectomy for prostate cancer.

Statistical Information

P-Value

<0.0001

Statistical Significance

p<0.0001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication